SAN ANTONIO, TX (October 7, 2015) bioAffinity Technologies, a privately held cancer diagnostics company, will seat two new members on its Board of Directors at the third-quarter meeting Oct. 26, 2015.
read moreSAN ANTONIO, TX (October 4, 2015) Early detection of cancer prolongs life. Each of us at bioAffinity Technologies has seen this firsthand. Our brothers, sisters, parents, friends and patients, and many of us personally, have benefited from early cancer detection.
read moreSAN ANTONIO, TX (September 30, 2015) bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio.
read moreSAN ANTONIO, TX (September 23, 2015) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that results from a 128-patient proof-of-concept clinical study for its non-invasive and quantitative assay for early-stage lung cancer were published in the Journal of Thoracic Oncology.
read moreThe clinical study demonstrated 81% accuracy in detecting cancer from sputum samples collected from participants in two cohorts. The high-risk cohort included military veterans who had smoked at least 20 pack-years.
read more